Sid. With all my respect. Regen is in the progress to buyout because they so far can’t take advantage to target they own pipeline. They don’t have a billion budget for that and for Koss time is money. For sure he don’t have time to wait a few years . Usually five years or more. But buyout can be a best deal for company. IMO Koss will sell company in the a few weeks or months and he will move on to the next company. I think he have already proposal and he is on the rush to get current . Many of the small company did that . Here you are Cancer, rare disease and, to a lesser extent, central nervous system players are targets that match up most closely with prospective buyers. Meanwhile, the scale of the industry’s product pipeline is at record highs, creating a big shop window for buyers to choose from.
Jared Holz, CPA, Healthcare Equity Strategy, Jefferies LLC—who was instrumental in helping Fierce Biotech come up with this year’s shortlist—says that while 2019 was remarkable for large-scale acquisitions, in 2020 “our sense is mid-size deals are more likely.”
He expects to see transactions in the $5 billion to $10 billion range and says many biotech companies who have often been featured on takeout lists—such as Seattle Genetics, Vertex Pharma and Regeneron—are likely too large in size now, and the window for any such deal has passed.
Among others on those lists, Alexion, BioMarin and Neurocrine Biosciences are probably at the higher end of the market-cap spectrum in terms of companies that could see themselves acquired by firms of greater size.
Looking a little beyond the companies on our top 10 list, other biotechs that could be the subject of deals include Arena Pharma, Avadel Pharma, Biohaven, Blueprint Medicines, Incyte, Karyopharm Therapeutics, Retrophin, SAGE Therapeutics, Sarepta, and uniQure.
Holz thinks the following large-cap firms are among those most likely to be active in M&A in the coming months: Amgen, Biogen, Bristol Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Novartis, Pfizer, and Sanofi.
Many of those companies are either already restructuring or are in need of it, and have management actively engaging with M&A as a tool for business development.
Market Data 
Markets 
AI
